Assay
Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| Roivant Sciences Ltd.ROIV · healthcare | |
|---|---|
| Grade |  Cmiddle fifth of 371 graded peers; percentile 54.1, sampling error 2.5 points; lower is stronger |
| Rank | 201 of 371 |
| Profitability | Epercentile 89.9 |
| Solvency | Apercentile 7.1 |
| Growth and financing | Cpercentile 51.2 |
| Reliability | 0.94 AUCfailure model, filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025 |
| Peer failure rate | 0.52% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | over $2.67B assetstotal assets $5.7B[1] |
| Standard universe | insiderevenue above $1M and assets above $10M[1-2] |
| Warnings | none active · fortress balance sheet |
| Inputs computable | 7 of 14 |
| Graded from | filings received through May 20, 2026142 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $34.222026-10-08; market equity $24.7B; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received May 20, 2026; the document on sec.gov.
Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes brepocitinib, a potent small molecule inhibitor of JAK1 and TYK2 currently under review at the FDA for the treatment of dermatomyositis and also in late stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung...
Warnings [top]
7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.
The Fourteen Inputs [top]
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 89.9 | |||||||
| Gross profitability | not computable | 32.2% | |||||
| one or more required annual facts are missing | |||||||
| Return on invested capital | not computable | 9.3% | |||||
| average invested capital must exceed $1,000,000 | |||||||
| Accruals ratio | 8.1% | [1,5-7] | (6.6%) | 89.9 | 811 | 2026-03-31 | |
| Gross margin stability, five years | not computable | 2.8 pts | |||||
| five annual gross margins are required; found 0 | |||||||
| Solvency, sleeve percentile 7.1 | |||||||
| Twelve-month failure probability | 0.02% | 0.07% | 12.6 | 248 | 2026-06-30 | ||
| Altman Z double-prime | 16.14 | [1,8-13] | (0.31) | 3.7 | 756 | 2026-03-31 | |
| Net debt to EBITDA | not computable | 1.82x | |||||
| latest aligned inputs end 2024-03-31; latest annual assets end 2026-03-31 | |||||||
| Interest coverage | not computable | (4.51x) | |||||
| latest aligned inputs end 2024-03-31; latest annual assets end 2026-03-31 | |||||||
| Current ratio | 18.37x | [8-9] | 2.96x | 4.9 | 839 | 2026-03-31 | |
| Growth and financing, sleeve percentile 51.2 | |||||||
| Revenue growth, three-year compound | (36.0%) | [2,14-16] | 10.0% | 93.2 | 415 | 2026-03-31 | |
| Free cash flow growth, three-year compound | not computable | 10.9% | |||||
| current FCF must be positive and base FCF must exceed $100,000 | |||||||
| Reinvestment rate | not computable | 37.1% | |||||
| pretax income must exceed the validity floor and imply a 0%-100% tax rate | |||||||
| Asset growth, three years | 33.7% | [1,7,17-18] | 2.1% | 13.8 | 704 | 2026-03-31 | |
| Net share issuance, one year | 5.8% | [19-20] | 2.5% | 46.6 | 634 | 2026-05-12 | |
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Sleeves are equal-weighted; within a sleeve each computable input carries equal weight. Composite -0.015; sampling error 2.5 percentile points on 371 peers.
Among 371 Peers [top]
Composite score of every graded peer, smoothed. Vertical rules are the letter band edges at the 20th, 40th, 60th and 80th percentiles. Small dots are the six largest peers by market equity.
| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 196 | Nexgel, Inc. (NXGL) Nexgel, Inc. (NXGL) Cmiddle fifth; percentile 52.8 Nasdaq · Surgical & Medical Instruments & Apparatus last close $0.15 Warnings: late filer; 7 of 14 inputs | 52.8 | C | late filer |
| 197 | Nexgel, Inc. (NXGLW) Nexgel, Inc. (NXGLW) Cmiddle fifth; percentile 52.8 Nasdaq · Surgical & Medical Instruments & Apparatus last close $0.01 Warnings: late filer; 7 of 14 inputs | 52.8 | C | late filer |
| 198 | Perrigo Co. plc (PRGO) Perrigo Co. plc (PRGO) Cmiddle fifth; percentile 53.2 NYSE · Pharmaceutical Preparations market equity $2.0B; last close $14.50 No active warnings; 9 of 14 inputs | 53.2 | C | |
| 199 | Sotera Health Co. (SHC) Sotera Health Co. (SHC) Cmiddle fifth; percentile 53.5 Nasdaq · Services-Misc Health & Allied Services, NEC market equity $5.1B; last close $17.84 No active warnings; 8 of 14 inputs | 53.5 | C | |
| 200 | Universal Health Services Inc. (UHS) Universal Health Services Inc. (UHS) Cmiddle fifth; percentile 53.8 NYSE · Services-General Medical & Surgical Hospitals, NEC last close $175.66 No active warnings; 9 of 14 inputs | 53.8 | C | |
| 201 | Roivant Sciences Ltd. (ROIV) Roivant Sciences Ltd. (ROIV) Cmiddle fifth; percentile 54.1 Nasdaq · Pharmaceutical Preparations market equity $24.7B; last close $34.22 Warnings: fortress balance sheet; 7 of 14 inputs | 54.1 | C | fortress balance sheet |
| 202 | Emergent BioSolutions Inc. (EBS) Emergent BioSolutions Inc. (EBS) Cmiddle fifth; percentile 54.3 NYSE · Pharmaceutical Preparations market equity $349.2M; last close $6.82 No active warnings; 10 of 14 inputs | 54.3 | C | |
| 203 | Abbott Laboratories (ABT) Abbott Laboratories (ABT) Cmiddle fifth; percentile 54.6 NYSE · Pharmaceutical Preparations market equity $171.6B; last close $98.49 No active warnings; 11 of 14 inputs | 54.6 | C | |
| 204 | Teladoc Health, Inc. (TDOC) Teladoc Health, Inc. (TDOC) Cmiddle fifth; percentile 54.9 NYSE · Services-Offices & Clinics of Doctors of Medicine market equity $1.0B; last close $5.53 Warnings: fortress balance sheet; 7 of 14 inputs | 54.9 | C | fortress balance sheet |
| 205 | Neuronetics, Inc. (STIM) Neuronetics, Inc. (STIM) Cmiddle fifth; percentile 55.1 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $163.1M; last close $2.15 No active warnings; 8 of 14 inputs | 55.1 | C | |
| 206 | Regenxbio Inc. (RGNX) Regenxbio Inc. (RGNX) Cmiddle fifth; percentile 55.4 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $534.0M; last close $8.08 Warnings: short runway; 7 of 14 inputs | 55.4 | C | short runway |
| Peer policy | Letter | Percentile | Peers |
|---|---|---|---|
| all graded filers, equal sleeves | D | 62.5 | 2204 |
| sector peers, equal sleeves (the grade) | C | 54.1 | 371 |
| same exchange, equal sleeves | C/D | 59.1 | 1219 |
| sector peers, equal inputs | A/B | 21.4 | 371 |
Each letter is one fifth of the 371 graded peers, about 74 companies. A boundary letter (A/B, B/C, C/D, D/E) marks a percentile within one sampling error of a band edge.
What the Price Implies [top]
Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | 128.9% | 8.0% | 92 | hotter than 92 of 100 peers |
| Distance from 52-week high | (18.2%) | (31.4%) | 68 | closer to its high than 68 of 100 peers |
| EBIT to enterprise value | (2.2%) | (1.5%) | 48 | pricier than 52 of 100 peers |
| Free cash flow yield | (3.1%) | (1.0%) | 44 | pricier than 56 of 100 peers |
| Book value to price | 0.17 | 0.28 | 37 | pricier than 63 of 100 peers |
| Sales to price | 0.00 | 0.31 | 2 | pricier than 98 of 100 peers |
| Composite equity issuance, five years | not computable | 20.3% | a share count from five years earlier is required | |
| Relative strength against the sector, log excess return | 0.62 | (0.14) | 92 | ahead of 92 of 100 peers |
Inputs: market equity $24.7B; EBIT -$515.1M; free cash flow -$758.6M; book equity $4.2B; sales $8.3M; debt $311.7M; cash $1.2B[21].
Diagnostics [top]
Diagnostics do not feed the grade.
| Piotroski F-score: None of 9, period end 2026-03-31 | ||
|---|---|---|
| Return on assets above zero | (5.5%) | ✗ fail[5,7] |
| Operating cash flow above zero | -$750.3M | ✗ fail[6] |
| Return on assets improved | (3.1 pts) | ✗ fail[5,7,17,22] |
| Operating cash flow exceeds net income | -$450.6M | ✗ fail[5-6] |
| Long-term leverage fell | n/a[1,7,17] | |
| Current ratio improved | (1,509.2 pts) | ✗ fail[8-9,23-24] |
| No new shares issued | 5.8% | ✗ fail[19-20] |
| Gross margin improved | n/a | |
| Asset turnover improved | (0.3 pts) | ✗ fail[2,7,14,17] |
| Cash, filings, liquidity | |
|---|---|
| Cash and equivalents | $1.2B[25] |
| Operating cash flow, four quarters | -$816.5M[6,25-29] |
| Months of runway | 18.3 |
| Late filings, two years | 0 |
| NT 10-K or NT 10-Q | |
| Days since last periodic filing | 64 |
| 10-Q received Aug 6, 2026 | |
| Median daily dollar volume | $204.8M |
| 63 sessions | |
| Days since newest grade input | 142 |
Downloads [top]
|
Sources [top]
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $5.7B | 2026-03-31 | 2026-05-20 | 10-K | filing · viewer · series |
| 2 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $8.3M | 2026-03-31 | 2026-05-20 | 10-K | filing · viewer · series |
| 3 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $6.5B | 2024-03-31 | 2025-05-29 | 10-K | filing · viewer · series |
| 4 | total debt | us-gaap:LongTermDebt | $430.6M | 2024-03-31 | 2024-05-30 | 10-K | filing · viewer · series |
| 5 | net income | us-gaap:NetIncomeLoss | -$299.8M | 2026-03-31 | 2026-05-20 | 10-K | filing · viewer · series |
| 6 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$750.3M | 2026-03-31 | 2026-05-20 | 10-K | filing · viewer · series |
| 7 | assets | us-gaap:Assets | $5.4B | 2025-03-31 | 2026-05-20 | 10-K | filing · viewer · series |
| 8 | current assets | us-gaap:AssetsCurrent | $5.2B | 2026-03-31 | 2026-05-20 | 10-K | filing · viewer · series |
| 9 | current liabilities | us-gaap:LiabilitiesCurrent | $281.2M | 2026-03-31 | 2026-05-20 | 10-K | filing · viewer · series |
| 10 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$501.8M | 2026-03-31 | 2026-05-20 | 10-K | filing · viewer · series |
| 11 | operating income | us-gaap:OperatingIncomeLoss | -$515.1M | 2026-03-31 | 2026-05-20 | 10-K | filing · viewer · series |
| 12 | book equity | us-gaap:StockholdersEquity | $4.5B | 2026-03-31 | 2026-05-20 | 10-K | filing · viewer · series |
| 13 | liabilities | us-gaap:Liabilities | $416.3M | 2026-03-31 | 2026-05-20 | 10-K | filing · viewer · series |
| 14 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $29.1M | 2025-03-31 | 2026-05-20 | 10-K | filing · viewer · series |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $32.7M | 2024-03-31 | 2026-05-20 | 10-K | filing · viewer · series |
| 16 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $31.5M | 2023-03-31 | 2025-05-29 | 10-K | filing · viewer · series |
| 17 | assets | us-gaap:Assets | $7.2B | 2024-03-31 | 2025-05-29 | 10-K | filing · viewer · series |
| 18 | assets | us-gaap:Assets | $2.4B | 2023-03-31 | 2024-05-30 | 10-K | filing · viewer · series |
| 19 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 719,270,385 | 2026-05-12 | 2026-05-20 | 10-K | filing · viewer · series |
| 20 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 679,806,070 | 2025-05-21 | 2025-05-29 | 10-K | filing · viewer · series |
| 21 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 722,323,015 | 2026-07-31 | 2026-08-06 | 10-Q | filing · viewer · series |
| 22 | net income | us-gaap:NetIncomeLoss | -$172.0M | 2025-03-31 | 2026-05-20 | 10-K | filing · viewer · series |
| 23 | current assets | us-gaap:AssetsCurrent | $5.0B | 2025-03-31 | 2026-05-20 | 10-K | filing · viewer · series |
| 24 | current liabilities | us-gaap:LiabilitiesCurrent | $149.4M | 2025-03-31 | 2026-05-20 | 10-K | filing · viewer · series |
| 25 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $1.2B | 2026-06-30 | 2026-08-06 | 10-Q | filing · viewer · series |
| 26 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$270.5M | 2026-06-30 | 2026-08-06 | 10-Q | filing · viewer · series |
| 27 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$586.5M | 2025-12-31 | 2026-02-06 | 10-Q | filing · viewer · series |
| 28 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$390.0M | 2025-09-30 | 2025-11-10 | 10-Q | filing · viewer · series |
| 29 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$204.4M | 2025-06-30 | 2026-08-06 | 10-Q | filing · viewer · series |
Limitations [top]
Grade boundary. Percentile 54.1 is 5.9 points from the nearest band edge; sampling error is 2.5 points.
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
